EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Squamous Cell Carcinoma in Never Smokers: An Insight into SMARCB1 Loss

Akshay J Patel, Hanan Hemead, Hannah Jesani, Andrea Bille, Philippe Taniere, Gary Middleton

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Akshay J Patel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15…. Hauptthemen laut MEDLINE: SMARCB1 Protein, Carcinoma, Squamous Cell, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) constituting 85% of cases. Among NSCLCs, squamous cell carcinoma (SqCC) is strongly associated with smoking. However, lung cancer in never smokers (LCINS) represents approximately 25% of lung cancer cases globally and shows increasing incidence, particularly in East Asia. LCINS-SqCC is less well-characterized, especially regarding its genomic alterations and their impact on clinical outcomes. We conducted a retrospective analysis over a 20-year period (July 2003–July 2023) at two major tertiary centers in the UK. The cohort included 59 patients with LCINS-SqCC who underwent radical surgical resection. Data collected included demographic information, comorbidities, histopathological details, and outcome metrics such as disease-free and overall survival. Molecular sequencing of tumor specimens was performed to identify genomic aberrations. The cohort had a median age of 71 years (IQR 62–77) and a median BMI of 25.4 (IQR 22.8–27.8), with a slight male predominance (53%). The majority of patients (93%) had a preoperative MRC of 1–2. Recurrent disease was observed in 23 patients (39%), and 32 patients (54%) had died at a median follow-up of 3 years. Median disease-free survival was 545 days (IQR 132–1496), and overall survival was 888 days (IQR 443–2071). Preoperative creatinine levels were higher in patients who experienced recurrence (p = 0.037). Molecular analysis identified biallelic SMARCB1 loss in two younger patients, associated with rapid disease progression despite R0 resection. These patients’ tumors were PDL1-negative, TTF-1-negative, and positive for cytokeratin, CD56, and p40. SMARCB1-deficient SqCC in never smokers represents a highly aggressive variant with poor disease-free survival, highlighting the importance of integrating advanced molecular diagnostics in clinical practice. This study underscores the necessity for personalized treatment strategies, including targeted therapies such as EZH2 inhibitors and immune checkpoint blockade, to address the unique molecular pathways in SMARCB1-deficient cancers. Further clinical trials are essential to optimize therapeutic approaches for this challenging subgroup of lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SMARCB1 ProteinCarcinoma, Squamous CellLung NeoplasmsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesCarcinoma, Non-Small-Cell LungNon-SmokersBiomarkers, Tumor

Stichwörter der Autor:innen

BAF complexSMARCB1SWF/INI complexlung cancer in never smokers (LCINS)non-small cell lung cancer (NSCLC)squamous cell carcinoma (SqCC)

Substanzen

SMARCB1 ProteinSMARCB1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK.
  • Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham B15 2GW, UK.
  • Department of Thoracic Surgery, Guy's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, UK.
  • Department of Cellular Histopathology, University Hospitals Birmingham, Birmingham B15 2GW, UK.

Zitieren

APA

Patel, A. J., Hemead, H., Jesani, H., Bille, A., Taniere, P., & Middleton, G. (2024). Squamous Cell Carcinoma in Never Smokers: An Insight into SMARCB1 Loss. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158165

Vancouver

Patel AJ, Hemead H, Jesani H, Bille A, Taniere P, Middleton G. Squamous Cell Carcinoma in Never Smokers: An Insight into SMARCB1 Loss. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158165

BibTeX
@article{Patel2024,
  author = {Patel, Akshay J and Hemead, Hanan and Jesani, Hannah and Bille, Andrea and Taniere, Philippe and Middleton, Gary},
  title = {Squamous Cell Carcinoma in Never Smokers: An Insight into SMARCB1 Loss},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158165}
}
Kostenlos starten →